Related references
Note: Only part of the references are listed.Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India
Dharna Gupta et al.
JCO Global Oncology (2023)
Clinical Review on the Management of Metastatic Renal Cell Carcinoma
Jennifer Tran et al.
JCO ONCOLOGY PRACTICE (2022)
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
Borje Ljungberg et al.
EUROPEAN UROLOGY (2022)
Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma
Yu-Wei Chen et al.
CURRENT ONCOLOGY REPORTS (2022)
Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review
Aly-Khan A. Lalani et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma
T. Powles et al.
ANNALS OF ONCOLOGY (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The role of immunotherapy in advanced renal cell carcinoma
Ercilia Rita Mondlane et al.
INTERNATIONAL BRAZ J UROL (2021)
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
Michael R. Harrison et al.
CANCER (2021)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma
R. Kanesvaran et al.
ESMO OPEN (2021)
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
New approaches to first-line treatment of advanced renal cell carcinoma
Daniel J. George et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)
Juhani Knuuti et al.
EUROPEAN HEART JOURNAL (2020)
Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
Kirsi M. Manz et al.
ADVANCES IN THERAPY (2020)
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T.K. Choueiri et al.
ANNALS OF ONCOLOGY (2020)
Research progress on advanced renal cell carcinoma
Xin-da Song et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2020)
The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic review
Shouki Bazarbashi et al.
FUTURE ONCOLOGY (2020)
Sequencing Therapies for Metastatic Renal Cell Carcinoma
Nazli Dizman et al.
UROLOGIC CLINICS OF NORTH AMERICA (2020)
Sarcomatoid renal cell carcinoma: biology, natural history and management
Kyle A. Blum et al.
NATURE REVIEWS UROLOGY (2020)
Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma
Annalisa Guida et al.
Oncotarget (2020)
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Laurence Albiges et al.
ESMO OPEN (2020)
Epidemiology of Renal Cell Carcinoma
Sandeep Anand Padala et al.
WORLD JOURNAL OF ONCOLOGY (2020)
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
Huan Deng et al.
BMC CANCER (2019)
Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database
Sumanta Pal et al.
BMC CANCER (2019)
Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma
Kazutaka Okita et al.
CLINICAL GENITOURINARY CANCER (2019)
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
Robert J. Motzer et al.
BRITISH JOURNAL OF CANCER (2018)
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Active Surveillance for Low-Risk Cancers - A Viable Solution to Overtreatment?
Megan R. Haymart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treatment of renal cell carcinoma: Current status and future directions
Pedro C. Barata et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis
Hendrik Eggers et al.
JOURNAL OF KIDNEY CANCER AND VHL (2017)
First-line treatment options in metastatic renal cell cancer
Anil Kapoor
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2016)
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
Brian I. Rini et al.
LANCET ONCOLOGY (2016)
Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy
Allard Noe et al.
WORLD JOURNAL OF UROLOGY (2016)
Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
Pooja Ghatalia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2013)
Clinical Consensus Statement: Tracheostomy Care
Ron B. Mitchell et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2013)
How to select amongst available options for the treatment of advanced RCC?
B. Escudier et al.
ANNALS OF ONCOLOGY (2012)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
Advances in renal cell carcinoma treatment
Marc-Oliver Grimm et al.
THERAPEUTIC ADVANCES IN UROLOGY (2010)
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma
TM Mekhail et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)